Protocol Ledger

NCT07144293 · Phase II · COMPLETED

Improving Physical Ability and Cellular Senescence Elimination in HIV

Interventional Phase II clinical trial protocol NCT07144293 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-04 Enrollment: 82 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07144293
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)82 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07144293
Protocol FieldVerified Registry Value
NCT IdentifierNCT07144293
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment82 participants (ACTUAL)
Registered Start Date2025-12-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI